Yep, it has to make you wonder if they even gave the raw data from the Covid ARDS trial to Novartis.
I couldn't help wondering at the time if one reason for the delay was a reluctance on the part of MSB to hand over data that Novartis needed to see, when SI just wanted to serve up the under 65 yr results. If Novartis had to extract the rest of the data bit by bit according to the contractual agreements, it might have taken a long time...
MSB 2022 - The road to commercialisation, page-1348
-
- There are more pages in this discussion • 181 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.55 |
Change
-0.025(1.59%) |
Mkt cap ! $1.792B | |||
| Open | High | Low | Value | Volume |
| $1.56 | $1.56 | $1.52 | $1.037M | 674.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 66999 | $1.54 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.55 | 9890 | 5 |
View Market Depth
| Last trade - 10.38am 18/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |